Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk.

Pfizer's stock has declined 34% over five years due to falling coronavirus product demand and patent expirations on key drugs. However, the company's recent strategic acquisitions (Seagen, Metsera, Biohaven), regulatory approvals, and cost restructuring efforts are showing positive results. With management confident in maintaining its 6% dividend yield and the stock trading at a reasonable 9.6x forward earnings, the pharmaceutical giant may now present a compelling opportunity for dividend investors.